WO2020259486A1 - 一种具有自愈合功能的丝胶水凝胶及其制备方法和应用 - Google Patents
一种具有自愈合功能的丝胶水凝胶及其制备方法和应用 Download PDFInfo
- Publication number
- WO2020259486A1 WO2020259486A1 PCT/CN2020/097675 CN2020097675W WO2020259486A1 WO 2020259486 A1 WO2020259486 A1 WO 2020259486A1 CN 2020097675 W CN2020097675 W CN 2020097675W WO 2020259486 A1 WO2020259486 A1 WO 2020259486A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sericin
- self
- sodium alginate
- hydrogel
- solution
- Prior art date
Links
- 108010013296 Sericins Proteins 0.000 title claims abstract description 104
- 239000000017 hydrogel Substances 0.000 title claims abstract description 72
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 49
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 49
- 239000000661 sodium alginate Substances 0.000 claims abstract description 49
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 49
- 239000000243 solution Substances 0.000 claims abstract description 45
- 238000006243 chemical reaction Methods 0.000 claims abstract description 25
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims abstract description 23
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000011259 mixed solution Substances 0.000 claims abstract description 8
- 239000002262 Schiff base Substances 0.000 claims abstract description 6
- 150000004753 Schiff bases Chemical class 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims abstract description 5
- 230000001737 promoting effect Effects 0.000 claims abstract description 5
- 230000011164 ossification Effects 0.000 claims abstract description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 24
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 24
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 13
- IBVAQQYNSHJXBV-UHFFFAOYSA-N adipic acid dihydrazide Chemical compound NNC(=O)CCCCC(=O)NN IBVAQQYNSHJXBV-UHFFFAOYSA-N 0.000 claims description 11
- 238000000502 dialysis Methods 0.000 claims description 9
- 125000003277 amino group Chemical group 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 7
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 125000003172 aldehyde group Chemical group 0.000 claims description 4
- 239000004744 fabric Substances 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 239000002861 polymer material Substances 0.000 claims description 2
- 239000002699 waste material Substances 0.000 claims description 2
- 230000000052 comparative effect Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 239000000499 gel Substances 0.000 description 11
- 239000000843 powder Substances 0.000 description 10
- 210000000988 bone and bone Anatomy 0.000 description 9
- 238000004132 cross linking Methods 0.000 description 9
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 8
- 230000006835 compression Effects 0.000 description 7
- 238000007906 compression Methods 0.000 description 7
- 239000008367 deionised water Substances 0.000 description 7
- 229910021641 deionized water Inorganic materials 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000012669 compression test Methods 0.000 description 6
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000002639 bone cement Substances 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000002188 osteogenic effect Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 108010022355 Fibroins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- ZQBZAOZWBKABNC-UHFFFAOYSA-N [P].[Ca] Chemical compound [P].[Ca] ZQBZAOZWBKABNC-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000008846 dynamic interplay Effects 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 230000009442 healing mechanism Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000002138 osteoinductive effect Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012890 simulated body fluid Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000009864 tensile test Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/46—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
- C08H1/00—Macromolecular products derived from proteins
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2389/00—Characterised by the use of proteins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2405/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2401/00 or C08J2403/00
- C08J2405/04—Alginic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K3/00—Use of inorganic substances as compounding ingredients
- C08K3/32—Phosphorus-containing compounds
- C08K2003/321—Phosphates
- C08K2003/325—Calcium, strontium or barium phosphate
Definitions
- the Chinese patent document with the application publication number CN 105268029 A discloses a method for preparing an injectable and self-healing natural polymer hydrogel for bone repair.
- sodium alginate and soluble periodate are combined.
- the aldehyde-based functionalized sodium alginate is generated by oxidation reaction, then calcium hydroxide and phosphoric acid are reacted to form calcium phosphate bone cement, and then the calcium phosphate bone cement is compounded with ethylene glycol chitosan, and then the aldehyde-based functionalized sodium alginate is combined
- It is prepared by Schiff base reaction in phosphate buffer solution.
- this technical solution needs to regulate pH when synthesizing calcium phosphate bone cement, and there is a certain gap between the crystallinity and calcium-phosphorus ratio of apatite in the organism, and the effect of bone repair may be poor.
- the present invention discloses a preparation method of sericin hydrogel with self-healing function.
- the prepared sericin hydrogel has excellent self-healing function and mechanical properties, and is especially suitable for Used to promote osteogenic function.
- a preparation method of sericin hydrogel with self-healing function includes the following steps:
- Sericin is a kind of natural macromolecular protein wrapped on the surface of silk fibroin. It has good biocompatibility and easy processing. It can be easily made into fibers, microspheres, films, hydrogels and other forms. material. In addition, sericin has a large number of polar groups (hydroxyl, carboxyl, and amino). This composition and structure endow sericin with the characteristics of easy cross-linking, controllable structure, and good biocompatibility. The carboxyl group of sericin itself can bind calcium ions well, so as to carry out electrostatic adsorption with nano-hydroxyapatite particles.
- the sericin is extracted from lower corner cocoons, waste silk or recycled spun silk fabric products; therefore, the production cost of the preparation process can be greatly reduced.
- the concentration of the sericin/dimethyl sulfoxide solution is 100-300 mg/mL;
- the concentration of the adipic acid dihydrazide/dimethyl sulfoxide solution is 300-800 mg/mL;
- the adjustment of the amount of adipic acid dihydrazide will affect the degree of crosslinking of the sericin hydrogel with self-healing function.
- the amount is lower than the above amount, the ratio of sericin amination is low, resulting in poor crosslinking degree and self-healing efficiency of sericin hydrogel; when the amount is higher than the above amount, the cost will increase, and it will be due to the overproduction of the product. Reaction affects biocompatibility.
- the concentration of the adipic acid dihydrazide/dimethyl sulfoxide solution is 600 mg/mL.
- the concentration of the sodium alginate aqueous solution is 5-20 mg/mL;
- the molar ratio of sodium alginate to sodium periodate is 1:0.5-1;
- the volume ratio of the ethylene glycol to the sodium alginate aqueous solution is 0.5 to 1.5: 100;
- the dialysis treatment in step (2) and step (3) uses a dialysis bag with a molecular weight cut-off of 3500D. It is found through experiments that the aminated sericin and oxidized algae after the two-step special specification dialysis bag are used Sodium, the cross-linking of the two is better.
- step (3)
- the concentration of aminated sericin is 50-200 mg/mL; as the concentration of the aminated sericin increases, the compactness of the internal microstructure of the hydrogel is enhanced to a certain extent, and the mechanical properties are increased ,
- the gel time is significantly shortened; below the above concentration range, the morphology formed is mainly loose and uneven; and above the above concentration range, the gel speed is too fast will also lead to incomplete crosslinking, and the morphology is too tight and not It is flat and uniform; further preferably, the concentration of the aminated sericin is 90-150 mg/mL.
- the concentration of oxidized sodium alginate in the solution is 50-200 mg/mL; through experiments, it is found that as the concentration of the sodium alginate aqueous solution increases, the compactness of the internal microstructure of the hydrogel is increased to a certain extent, and the mechanical properties are increased , The gel time is significantly shortened; below the above concentration range, the morphology formed is mainly loose and uneven; and above the above concentration range, the gel speed is too fast will also lead to incomplete crosslinking, and the morphology is too tight and not It is flat and uniform; further preferably, the concentration of the oxidized sodium alginate is 90-150 mg/mL.
- the sericin hydrogel prepared by the invention has excellent self-healing function, the healing process does not require external stimuli (pH, light, temperature, chemical reagents, etc.); as well as excellent compression resistance and toughness, and better mechanical properties. Compared with other common natural macromolecular materials (such as gelatin), the hydrogels have better overall performance, and have better binding effects with hydroxyapatite.
- the preparation process of the invention has the advantages of low energy consumption, high biological safety, low price, simple and convenient operation, short time, mild reaction conditions, and high yield.
- Figure 1 is a microphotograph of the sericin hydrogel prepared in Example 1;
- Ultrasound for 30 minutes mix the aminated sericin solution mixed with hydroxyapatite and the oxidized sodium alginate solution at a volume ratio of 1:1 to control the amino groups in the aminated sericin and the aldehydes in the oxidized sodium alginate
- the molar ratio of the base is 1:1, and a self-healing sericin hydrogel with excellent mechanical properties is obtained.
- the preparation process is the same as in Example 1, except that 6 g of sericin powder is replaced with 6 g of gelatin powder.
- the preparation process is the same as in Example 1, except that hydroxyapatite powder is not added.
- the preparation process is the same as that in Comparative Example 2, except that 6 g of sericin powder is replaced with 6 g of gelatin powder.
- the maximum stress of the hydrogel prepared in this comparative example is 92 kPa and the maximum strain is 47%.
- the preparation process is the same as in Example 1, except that the added amount of hydroxyapatite powder is replaced by 20% and 60% of the sericin mass respectively.
- the sericin hydrogel prepared in this example has excellent self-healing performance, and the healing efficiency reaches 76.5% after 12 hours.
- the maximum stress of the hydrogel prepared in this example is 173 kPa and the maximum strain is 38%.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Dispersion Chemistry (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Composite Materials (AREA)
- Molecular Biology (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (11)
- 一种具有自愈合功能的丝胶水凝胶的制备方法,其特征在于,包括如下步骤:(1)以丝胶为原料,制备胺基化丝胶;(2)以海藻酸钠为原料,制备氧化海藻酸钠;(3)将步骤(1)制备的胺基化丝胶、羟基磷灰石与水混合,得到混合溶液;(4)将步骤(2)制备的氧化海藻酸钠与水混合得到溶液,再将所述溶液与步骤(3)所述混合溶液混合,经席夫碱反应得到所述具有自愈合功能的丝胶水凝胶。
- 根据权利要求1所述的具有自愈合功能的丝胶水凝胶的制备方法,其特征在于,步骤(1)中,所述胺基化丝胶的具体制备工艺如下:向丝胶/二甲基亚砜溶液中,加入羰基二咪唑充分反应,将混合液倒入己二酸二酰肼/二甲基亚砜溶液中,反应12~36h,反应液经透析处理、冷冻干燥后得到胺基化丝胶。
- 根据权利要求2所述的具有自愈合功能的丝胶水凝胶的制备方法,其特征在于:所述丝胶由下角茧、废丝或回收再生的绢丝织物品中提取得到。
- 根据权利要求2所述的具有自愈合功能的丝胶水凝胶的制备方法,其特征在于:所述丝胶/二甲基亚砜溶液的浓度为100~300mg/mL;所述己二酸二酰肼/二甲基亚砜溶液的浓度为300~800mg/mL;所述羰基二咪唑、丝胶和己二酸二酰肼的质量比为1:1~2:10~20。
- 根据权利要求1所述的具有自愈合功能的丝胶水凝胶的制备方法,其特征在于,步骤(2)中,所述氧化海藻酸钠的具体制备工艺如下:向海藻酸钠水溶液中,加入高碘酸钠,室温下避光反应2~6h,再加入乙二醇终止反应,反应液经透析、冷冻干燥后得到氧化海藻酸钠。
- 根据权利要求5所述的具有自愈合功能的丝胶水凝胶的制备方法,其特征在于:所述海藻酸钠水溶液的浓度为5~20mg/mL;所述海藻酸钠与高碘酸钠的摩尔比为1:0.5~1;所述乙二醇与所述海藻酸钠水溶液的体积比为0.5~1.5:100。
- 根据权利要求1所述的具有自愈合功能的丝胶水凝胶的制备方法,其特征在于,步骤(3)中:所述胺基化丝胶与羟基磷灰石的质量比为1:0.1~0.6;所述混合溶液中,胺基化丝胶的浓度为50~200mg/mL。
- 根据权利要求1所述的具有自愈合功能的丝胶水凝胶的制备方法,其特征在于,步骤(4)中:所述溶液中氧化海藻酸钠的浓度为50~200mg/mL;所述胺基化丝胶中的氨基与所述氧化海藻酸钠中的醛基的摩尔比为0.5~2:1。
- 一种根据权利要求1~8任一权利要求所述的方法制备的具有自愈合功能的丝胶水凝胶。
- 一种根据权利要求9所述的具有自愈合功能的丝胶水凝胶在促成骨功能中的应用。
- 一种根据权利要求9所述的具有自愈合功能的丝胶水凝胶在制备具有促成骨功能的高分子材料中的应用
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910566405.4 | 2019-06-27 | ||
CN201910566405.4A CN110283337B (zh) | 2019-06-27 | 2019-06-27 | 一种具有自愈合功能的丝胶水凝胶及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020259486A1 true WO2020259486A1 (zh) | 2020-12-30 |
Family
ID=68007720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/097675 WO2020259486A1 (zh) | 2019-06-27 | 2020-06-23 | 一种具有自愈合功能的丝胶水凝胶及其制备方法和应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN110283337B (zh) |
WO (1) | WO2020259486A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110283337B (zh) * | 2019-06-27 | 2020-07-24 | 浙江大学 | 一种具有自愈合功能的丝胶水凝胶及其制备方法和应用 |
CN113336974B (zh) * | 2021-07-21 | 2022-06-10 | 浙江大学 | 一种具有流动性、易降解的组氨酸基配位水凝胶及其制备方法和应用 |
CN114984326B (zh) * | 2022-06-02 | 2023-12-05 | 中国科学院大学宁波华美医院 | 一种多重交联的可注射骨修复水凝胶制备材料及其制备方法 |
CN116999617A (zh) * | 2023-06-25 | 2023-11-07 | 西南医科大学附属口腔医院 | 一种丝胶蛋白-羟基磷灰石/海藻酸钠载药微球的制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013103956A1 (en) * | 2012-01-05 | 2013-07-11 | President And Fellows Of Harvard College | Interpenetrating networks with covalent and ionic crosslinks |
CN106334192A (zh) * | 2015-07-10 | 2017-01-18 | 华中科技大学同济医学院附属协和医院 | 一种丝胶蛋白水凝胶及其制备方法和应用 |
CN106620825A (zh) * | 2016-12-26 | 2017-05-10 | 浙江大学 | 一种双组分快速止血凝胶及其应用 |
WO2018100340A1 (en) * | 2016-11-29 | 2018-06-07 | Fujifilm Manufacturing Europe Bv | Hydrogels |
CN109806443A (zh) * | 2017-11-21 | 2019-05-28 | 中国科学院化学研究所 | 骨支架材料及其制备方法和应用 |
CN110283337A (zh) * | 2019-06-27 | 2019-09-27 | 浙江大学 | 一种具有自愈合功能的丝胶水凝胶及其制备方法和应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180133368A1 (en) * | 2016-11-15 | 2018-05-17 | The Board Of Regents Of The University Of Texas System | 3D Printed Ti-6Al-4V Scaffolds with Hydrogel Matrix |
-
2019
- 2019-06-27 CN CN201910566405.4A patent/CN110283337B/zh active Active
-
2020
- 2020-06-23 WO PCT/CN2020/097675 patent/WO2020259486A1/zh active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013103956A1 (en) * | 2012-01-05 | 2013-07-11 | President And Fellows Of Harvard College | Interpenetrating networks with covalent and ionic crosslinks |
CN106334192A (zh) * | 2015-07-10 | 2017-01-18 | 华中科技大学同济医学院附属协和医院 | 一种丝胶蛋白水凝胶及其制备方法和应用 |
WO2018100340A1 (en) * | 2016-11-29 | 2018-06-07 | Fujifilm Manufacturing Europe Bv | Hydrogels |
CN106620825A (zh) * | 2016-12-26 | 2017-05-10 | 浙江大学 | 一种双组分快速止血凝胶及其应用 |
CN109806443A (zh) * | 2017-11-21 | 2019-05-28 | 中国科学院化学研究所 | 骨支架材料及其制备方法和应用 |
CN110283337A (zh) * | 2019-06-27 | 2019-09-27 | 浙江大学 | 一种具有自愈合功能的丝胶水凝胶及其制备方法和应用 |
Non-Patent Citations (2)
Title |
---|
DING FUYUAN, WU SHUPING, WANG SHISHUAI, XIONG YUAN, LI YAN, LI BIN, DENG HONGBING, DU YUMIN, XIAO LING, SHI XIAOWEN: "A Dynamic and Self-Crosslinked Polysaccharide Hydrogel with Autonomous Self-Healing Ability", SOFT MATTER, vol. 11, no. 20, 28 May 2015 (2015-05-28), pages 3971 - 3976, XP055773965, ISSN: 1744-683X, DOI: 10.1039/c5sm00587f * |
WANG LIN-TING, YANG MING-YING, ZHU LIANG-JUN, ZHANG HAI-PING, MIN SI-JIA, DENG LIAN, -XIA: "Preparation and Performance of Silk Sericin/Hydroxyapatite Composite Bone Scaffold", SCIENCE OF SERICULTURE, vol. 36, no. 4, 15 August 2010 (2010-08-15), pages 639 - 644, XP055773970, ISSN: 0257-4799, DOI: 10.13441/j.cnki.cykx.2010.04.025 * |
Also Published As
Publication number | Publication date |
---|---|
CN110283337A (zh) | 2019-09-27 |
CN110283337B (zh) | 2020-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020259486A1 (zh) | 一种具有自愈合功能的丝胶水凝胶及其制备方法和应用 | |
Li et al. | Controlling molecular conformation of regenerated wild silk fibroin by aqueous ethanol treatment | |
Bundela et al. | Designing of hydroxyapatite-gelatin based porous matrix as bone substitute: Correlation with biocompatibility aspects | |
US20210038760A1 (en) | Biomimetic bone composite material, a preparation method and uses thereof | |
CN110548171B (zh) | 一种明胶基骨组织粘合剂、其制备方法和应用 | |
CN101401965A (zh) | 一种复合骨修复生物活性材料的合成方法 | |
CN110585485A (zh) | 一种竹纤维/羟基磷灰石/壳聚糖新型复合膜及制备方法 | |
CN110152055A (zh) | 海藻酸胺化衍生物/细菌纤维素纳米晶复合凝胶构筑的功能性药物缓释医用敷料 | |
CN112957525A (zh) | 一种纳米羟基磷灰石/丝素蛋白/纤维素复合气凝胶及其制备方法 | |
CN110078943B (zh) | 层状矿化的纳米几丁质复合水凝胶、制备方法及复合材料 | |
CN101401966A (zh) | 一种复合骨修复生物活性材料的制备方法 | |
CN112957515B (zh) | 一种生物活性玻璃/凝血酶复合止血粉末及其制备方法及应用 | |
CN114848906B (zh) | 一种SF/SiO2复合材料 | |
CN116396499A (zh) | 一种多巴胺改性纳米复合水凝胶及其制备方法 | |
CN115887742B (zh) | 抗菌功能性胶原基可注射自修复水凝胶的制备方法 | |
CN113174091B (zh) | 一种茶叶纤维素纳米晶/非水溶性蛋白复合膜及其制备方法和应用 | |
CN111793225B (zh) | 一种明胶/结冷胶/羟基磷灰石复合水凝胶及其制备方法 | |
CN110801529B (zh) | 一种改性细菌纤维素/肝素/明胶医用敷料及其制备方法 | |
CN114984326B (zh) | 一种多重交联的可注射骨修复水凝胶制备材料及其制备方法 | |
CN113975450B (zh) | 一种丝素蛋白复合材料倒刺缝合线及其制备方法 | |
CN113638221B (zh) | 一种具有生物活性的聚丙烯腈纤维及其制备方法 | |
Bajpai et al. | Development of poly (acrylamide)‐hydroxyapatite composites as bone substitutes: Study of mechanical and blood compatible behavior | |
CN115634314B (zh) | 一种非支撑骨修复凝胶微球及其制备方法 | |
CN115109321B (zh) | 一种腐植酸基纳米超多孔气凝胶及其制备方法 | |
JP3379088B2 (ja) | 生体材料用複合体およびその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20832932 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20832932 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 16/09/2022) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20832932 Country of ref document: EP Kind code of ref document: A1 |